You just read:

U.S. FDA Grants Priority Review of XARELTO® (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism (VTE)

News provided by

Janssen Research & Development, LLC

Jun 28, 2017, 08:30 ET